AMGN, PWRM, NHPR, CHTR, TIBX - Market Update From DrStockPick.com!
Sunday, July 3rd, 2011
Amgen Inc. (Nasdaq:AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved modified language in the prescribing information for the use of erythropoiesis-stimulating agents (ESAs), including Aranesp® (darbepoetin alfa) and EPOGEN® (Epoetin alfa), in patients with chronic kidney disease (CKD). The modified language, including changes to the Boxed Warning, provides important new information for the treatment of patients with CKD who are on dialysis, as well as those not on dialysis, to inform prescribers and patients of safety risks that have been identified in clinical trials. In recognition of the different benefit-risk profiles of ESA therapy in patients on dialysis compared to patients not on dialysis, the modified labeling provides separate treatment guidance for these two CKD populations.
Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada.
************************************************
People with ALS gradually become more disabled. How quickly the disease gets worse is different for everyone. Some people live with ALS for several years. But over time, ALS makes it hard to walk, speak, eat, swallow, and breathe. These problems can lead to injury, illness, and eventually death. In most cases, death will occur within 3 to 5 years after symptoms begin, although some people do live for many years, even decades.
Power3 Medical Products, Inc. (OTC.BB:PWRM) is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).
Power3 Medical Products, Inc. applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
The NuroPro Blood Test is Power3’s medical diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease), and Parkinson’s disease. Early detection of these diseases will allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.
Please visit Power3 Medical Products, Inc website http://www.power3medical.com.
************************************************

More than 50 million Americans are uninsured: More than 7 million of them are children; more than eight out of 10 are in working families. They are our friends, neighbors and colleagues–forced to gamble every day that they won’t get sick or injured.
Living without health insurance is a risk no one should have to take.
The healthcare industry remains in a state of turmoil and crisis. Each year, the cost of insurance skyrockets. The uninsured rate is higher among people with lower incomes.
The need for affordable healthcare alternatives has never been greater.
National Health Partners, Inc., (NHPR.OB), a leading provider of discount healthcare membership programs, announced the recent signing of two new significant marketing agreements. These two clients provide very different opportunities and continue to expand the reach of CARExpress into new marketplaces.
By launching their own unique internet marketing program, the first group should be able to provide a widespread push into the on-line market to produce an excellent volume of new CARExpress sales into the pipeline. In addition, the second group offers a reach into the wholesale marketplace where CARExpress will be wrapped into other programs to enhance the value of the overall package to the consumer. They would consider this non-traditional business and a great opportunity to expand their reach as well as recognition of the CARExpress program nationwide.
The company plans to announce the rollout of these new marketing campaigns as well as several others over the next few weeks.
More about NHPR at www.nationalhealthpartners.com
************************************************
Charter Communications Inc. (Nasdaq:CHTR) announced that Michael Lovett, President and Chief Executive Officer, will participate in the Guggenheim Media Symposium Conference this morning in New York, NY. Mr. Lovett is participating in a broadband distribution panel discussion that is expected to begin at approximately 11:00 am ET. A live audio webcast will be available online on Charter’s website at www.charter.com. The webcast can be accessed by selecting “Investor & News Center” from the lower menu on the home page, then “Financial Information”. To listen to the live webcast, please go to the website at least 15 to 20 minutes prior to the start to register, as well as download and install any necessary software. A replay will be available shortly after the conclusion of the presentation through midnight ET on July 6, 2011.
Charter Communications, Inc. provides cable services to residential and commercial customers in the United States.
************************************************
Tibco Software, Inc. (Nasdaq:TIBX) announced that it hosted a live launch event on Tuesday, June 28 to unveil tibbr® 3.0, the third generation of its enterprise social computing platform that is transforming the way companies collaborate. tibbr builds on TIBCO’s decades of experience in linking enterprise software systems, and connects not just people, but also systems, processes, applications, and subjects and makes them part of the conversation.
TIBCO Software Inc. provides middleware and infrastructure software worldwide. It offers its products in the areas of service-oriented architecture (SOA), business optimization, and business process management (BPM).
*************************************************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.
Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).
Crown Equity Holdings Inc. (CRWE.OB) has received 3,000,000 shares of (144) restricted common stock from the company and 3,000,000 shares of free trading shares from a third party (PIERRE BESUCHET) for six months of advertisement services for National Health Partners Inc. (NHPR.OB).














